SNDX
HEALTHCARESyndax Pharmaceuticals Inc
$20.65+0.55 (+2.74%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SNDX Today?
No stock-specific AI insight has been generated for SNDX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.58$25.59
$20.65
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-2.79
Dividend Yield—
Dividend / Share—
ROE-1.9%
Profit Margin-1.1%
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding88.6M
SNDX News
20 articles- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·May 6, 2026
- Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?Yahoo Finance·May 1, 2026
- Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...Yahoo Finance·May 1, 2026
- Syndax Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 1, 2026
- Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·Apr 30, 2026
- Syndax Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·Apr 30, 2026
- Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026Yahoo Finance·Apr 24, 2026
- This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight ResetMotley Fool·Mar 22, 2026
- High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest HoldingMotley Fool·Mar 21, 2026
- This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should KnowMotley Fool·Mar 21, 2026
- This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should KnowMotley Fool·Mar 21, 2026
- Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems BullishMotley Fool·Mar 21, 2026
- Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge?Yahoo Finance·Mar 18, 2026
- Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million InvestmentMotley Fool·Mar 13, 2026
- Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings PlannedMotley Fool·Mar 13, 2026
- uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts247 Wall St·Mar 9, 2026
- Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship DrugsYahoo Finance·Mar 2, 2026
- Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story?Yahoo Finance·Feb 28, 2026
- Syndax (SNDX) Q4 2025 Earnings Call TranscriptMotley Fool·Feb 27, 2026
- Syndax Pharmaceuticals, Inc. Q4 2025 Earnings Call SummaryMoby·Feb 27, 2026
All 20 articles loaded
Price Data
Open$20.83
Previous Close$20.10
Day High$21.22
Day Low$19.00
52 Week High$25.59
52 Week Low$8.58
52-Week Range
$8.58$25.59
$20.65
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-2.79
Dividend Yield—
Dividend / Share—
ROE-1.9%
Profit Margin-1.1%
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding88.6M
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—